HUP0100950A2 - Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0100950A2
HUP0100950A2 HU0100950A HUP0100950A HUP0100950A2 HU P0100950 A2 HUP0100950 A2 HU P0100950A2 HU 0100950 A HU0100950 A HU 0100950A HU P0100950 A HUP0100950 A HU P0100950A HU P0100950 A2 HUP0100950 A2 HU P0100950A2
Authority
HU
Hungary
Prior art keywords
group
general formula
optionally substituted
compounds
alkyl
Prior art date
Application number
HU0100950A
Other languages
English (en)
Inventor
Fumitoshi Asai
Toshihiko Ikeda
Teruhiko Inoue
Harou Iwabuchi
Ryo Iwamura
Yoshiaki Kuroki
Nobuhiko Shibakawa
Atsuhiro Sugidachi
Original Assignee
Sankyo Company, Limited
Ube Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited, Ube Industries, Ltd. filed Critical Sankyo Company, Limited
Publication of HUP0100950A2 publication Critical patent/HUP0100950A2/hu
Publication of HUP0100950A3 publication Critical patent/HUP0100950A3/hu
Publication of HU225741B1 publication Critical patent/HU225741B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)

Abstract

A találmány az (I) általános képletű gyűrűs aminovegyületekre és ezekgyógyászatilag elfogadható sóira, továbbá ilyen vegyületekettartalmazó gyógyászati készítményekre, valamint a vegyületekelőállítására szolgáló eljárásra vonatkozik. Az (I) általánosképletben R1 jelentése halogénatommal vagy alkil-, fluoralkil-,alkoxi-, fluoralkoxi-, ciano- vagy nitrocsoporttal adott esetbenszubsztituált fenilcsoport; R2 jelentése halogénatommal vagy alkoxi-,vagy cianocsoporttal adott esetben szubsztituált alifás acilcsoport,halogénatommal vagy alkil- vagy alkoxicsoporttal adott esetbenszubsztituált benzoilcsoport, vagy pedig alkoxikarbonilcsoport; és R3jelentése szubsztituált, 3-7-tagú telített gyűrűs aminocsoport, amelyadott esetben kondenzált gyűrű része lehet, mimellett ez a gyűrűsaminocsoport szubsztituálva lehet -S-XR4 általános képletű csoporttal[ebben a csoportban R4 jelentése halogénatommal vagy alkil-, alkoxi-,nitro- vagy cianocsoporttal adott esetben szubsztituált fenilcsoport,adott esetben szubsztituált alkilcsoport[ennek szubsztituense akövetkező csoportok valamelyike lehet: aminocsoport, hidroxilcsoport,karboxilcsoport, alkoxikarbonilcsoport, -NH-A1 általános képletűcsoport (ebben a képletben A1 jelentése a-aminosavból leszármaztathatómaradék) vagy -CO-A2 általános képletű csoport (ebben a képletben A2jelentése a-aminosavból leszármaztatható maradék)] vagycikloalkilcsoport, és X jelentése kénatom, szulfinilcsoport vagyszulfonilcsoport], továbbá ez a gyűrűs aminocsoport adott esetbentovábbi szubsztituensként valamely =CR5R6 általános képletű csoporttallehet helyettesítve[ebben az általános képletben R5 és R6 egymástólfüggetlenül hidrogénatomot vagy alkil-, karboxi-, alkoxikarbonil-,karbamoil-, alkilkarbamoil- vagy dialkilkarbamoilcsoportot jelent]. Az(I) általános képletű vegyületek vérlemezke-aggregációt inhibitálóhatással rendelkeznek. A találmány szerinti gyógyászati készítményekalkalmasak embólia, trombózis vagy érelmeszedés kezelésére vagymegelőzésére. Ó
HU0100950A 1998-02-27 1999-02-26 Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them HU225741B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4692198 1998-02-27
PCT/JP1999/000924 WO1999043648A1 (fr) 1998-02-27 1999-02-26 Composes amino cycliques

Publications (3)

Publication Number Publication Date
HUP0100950A2 true HUP0100950A2 (hu) 2001-08-28
HUP0100950A3 HUP0100950A3 (en) 2002-12-28
HU225741B1 HU225741B1 (en) 2007-07-30

Family

ID=12760807

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100950A HU225741B1 (en) 1998-02-27 1999-02-26 Cyclic amino compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (1) US6610708B1 (hu)
EP (1) EP1063230B1 (hu)
KR (1) KR100567950B1 (hu)
CN (1) CN100369896C (hu)
AT (1) ATE238279T1 (hu)
AU (1) AU737303B2 (hu)
BR (1) BRPI9908319B8 (hu)
CA (1) CA2322171C (hu)
CZ (1) CZ300821B6 (hu)
DE (1) DE69907166T2 (hu)
DK (1) DK1063230T3 (hu)
ES (1) ES2196772T3 (hu)
HU (1) HU225741B1 (hu)
ID (1) ID25589A (hu)
IL (1) IL138068A (hu)
MX (1) MXPA00008439A (hu)
NO (1) NO317882B1 (hu)
NZ (1) NZ506574A (hu)
PL (1) PL200666B1 (hu)
PT (1) PT1063230E (hu)
RU (1) RU2203887C2 (hu)
TR (1) TR200002505T2 (hu)
WO (1) WO1999043648A1 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051913A1 (ja) * 2003-11-28 2005-06-09 Sankyo Company, Limited ヘテロアリール環を有する環状アミン誘導体
CA2570637A1 (en) 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1889835A4 (en) * 2005-05-27 2010-04-28 Daiichi Sankyo Co Ltd CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175359A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9765020B2 (en) 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104603100A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗炎症性肠病的组合物和方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
SG10201700204TA (en) * 2013-01-09 2017-03-30 Univ Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 炎症及び疼痛の治療のための組成物及び方法
US10173980B2 (en) 2015-04-30 2019-01-08 The Regents Of The University Of Michigan Mixed disulfide conjugates of thienopyridine compounds and uses thereof
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554302A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554369A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
US11642335B2 (en) * 2019-09-26 2023-05-09 Board Of Regents, The University Of Texas System Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
CN111484446A (zh) * 2020-04-02 2020-08-04 北京翼方生物科技有限责任公司 氯吡格雷代谢活性体二硫衍生物、其制备方法及医药用途
CN111848497A (zh) * 2020-07-28 2020-10-30 内蒙古医科大学 氯吡格雷活性代谢物衍生物、其前药及其制备方法与应用
CN112851570A (zh) * 2021-01-13 2021-05-28 北京沃邦医药科技有限公司 不饱和环胺半胱氨酸二硫衍生物制备方法及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US555854A (en) * 1896-03-03 Brush-handle attachment
US3647796A (en) * 1968-12-23 1972-03-07 Parke Davis & Co Cyclicamino alkylaminothioacridine
FR2215948B1 (hu) 1973-02-01 1976-05-14 Centre Etd Ind Pharma
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
AU3351293A (en) * 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
DK0621037T3 (da) 1993-04-23 2000-01-17 Hoechst Ag Pyridopyrimidindioner, fremgangsmåder til deres fremstilling samt deres anvendelse som lægemidler
JPH09504274A (ja) 1993-09-17 1997-04-28 ブリガム アンド ウィメンズ ホスピタル 人工表面および血管面の血栓を予防する酸化窒素付加物の利用
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives

Also Published As

Publication number Publication date
CZ300821B6 (cs) 2009-08-19
HU225741B1 (en) 2007-07-30
NO20004279L (no) 2000-10-26
DK1063230T3 (da) 2003-07-14
EP1063230B1 (en) 2003-04-23
DE69907166T2 (de) 2004-02-05
CN100369896C (zh) 2008-02-20
PL342573A1 (en) 2001-06-18
PT1063230E (pt) 2003-07-31
BRPI9908319A (pt) 2000-11-07
DE69907166D1 (de) 2003-05-28
KR100567950B1 (ko) 2006-04-05
RU2203887C2 (ru) 2003-05-10
CA2322171C (en) 2009-10-27
NO317882B1 (no) 2004-12-27
US6610708B1 (en) 2003-08-26
TR200002505T2 (tr) 2000-12-21
PL200666B1 (pl) 2009-01-30
EP1063230A1 (en) 2000-12-27
AU2641399A (en) 1999-09-15
IL138068A0 (en) 2001-10-31
ATE238279T1 (de) 2003-05-15
NO20004279D0 (no) 2000-08-25
HUP0100950A3 (en) 2002-12-28
BRPI9908319B1 (pt) 2012-01-10
BRPI9908319B8 (pt) 2021-07-06
MXPA00008439A (es) 2002-04-24
NZ506574A (en) 2003-06-30
WO1999043648A1 (fr) 1999-09-02
EP1063230A4 (en) 2001-12-12
CA2322171A1 (en) 1999-09-02
IL138068A (en) 2005-11-20
CZ20003119A3 (cs) 2001-01-17
ID25589A (id) 2000-10-19
CN1298389A (zh) 2001-06-06
KR20010041367A (ko) 2001-05-15
ES2196772T3 (es) 2003-12-16
AU737303B2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
HUP0100950A2 (hu) Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények
EA200900358A1 (ru) Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
HUP0401740A2 (hu) N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
HUP0300148A2 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0102851A2 (hu) Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
HUP0301249A2 (hu) APO B termelődés gátló benzamid-vegyületek ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0401083A2 (hu) 4-Amino-6-fenil-pirrolo[2,3-d]pirimidin-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0001498A2 (hu) Farnezil-transzferáz-gátló 1,8-anellált imidazolil-kinolinon-származékok, intermedierjeik, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HUP0203122A2 (hu) Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0303729A2 (hu) Akridinszármazékok és azok gyógyszerként történő alkalmazása és eljárás az előállításukra
HUP0402313A2 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0100601A2 (hu) N-tartalmú biciklusos vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402026A2 (hu) 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0402065A2 (hu) Heterobiciklikus szerkezetû hepatitis C vírus polimeráz inhibitorok, eljárás az elõállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200600892A1 (ru) Новые хинолиновые производные
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
HUP0303458A2 (hu) 6-Helyettesített pirido-pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0002843A2 (hu) Új béta-karbolin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
HUP0203739A2 (hu) A hatos-gyűrűn helyettesített biciklikus imidazo-3-il-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE485822T1 (de) Phenylaminopyridine und phenylaminopyrazine